Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...

Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

Under the leadership of Mr. Todisco, CorMedix has evolved from a single product, development stage company into a multi-product, diversified commercial operation with positive cashflow and a strong ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...

Basilea Pharmaceutica has entered into a strategic collaboration with Prokaryotics to develop a first-in-class broad-spectrum antifungal therapy targeting severe invasive fungal infections. The ...

Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Successful management of denture-associated candidiasis relies heavily on mechanical disinfection rather than pharmacologic ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

An invasive yeast fungus called Candida auris is rapidly spreading around the world and is increasingly resistant to ...

Maiya Multispeciality Hospital, Jayanagar, successfully treated a 78-year-old male patient suffering from acute calculous ...